CG MED EQUIP.
838810
BEOKA
870199
Shenzhen Bromake New Material
301387
4
Zhejiang Hongchang Electrical Technology
301008
5
Wuhan Lincontrol Automotive Electronics Co., Ltd.
688667
CN Stock MarketDetailed Quotes
688505 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.
- 7.83
- +0.22+2.89%
Market Closed Apr 30 15:00 CST
8.12BMarket Cap200.77P/E (TTM)
7.88High7.66Low35.38KlotVolume7.68Open7.61Pre Close27.51MTurnover0.50%Turnover Ratio206.05P/E (Static)1.04BShares10.2952wk High3.52P/B5.56BFloat Cap6.0252wk Low9.13Limit Up710.57MShs Float42.07Historical High6.09Limit Down2.89%Amplitude6.02Historical Low0.09Dividend TTM7.78Avg Price14.92KlotAsk1.15%Div YieldTTM100Lot Size20.15KlotBid
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. News
Fudan and Zhangjiang announcement on drug price adjustments
Fudan Zhangjiang: Fudan Zhangjiang Notice on Convening the 2024 Annual General Meeting of Shareholders
Fudan Zhangjiang 2024 Annual General Meeting of Shareholders Meeting Materials
Fudan Zhangjiang Notice on Convening the 2024 Annual General Meeting of Shareholders
Fudan Zhangjiang: Fudan Zhangjiang Announcement on Renewal of the Employment of Accounting Firms
Fudan Zhangjiang: Fudan Zhangjiang 2024 Independent Director Debriefing Report (Xu Peilong)
Fudan Zhangjiang: Fudan Zhangjiang Board of Directors Special Opinions on the Independence of Independent Directors
Fudan Zhangjiang: Fudan Zhangjiang 2024 Independent Director Debriefing Report (Lin Zhaorong)
Fudan Zhangjiang: Fudan Zhangjiang 2024 Independent Director Debriefing Report (Wang Hongguang)
Fudan Zhangjiang 2024 Internal Control Evaluation Report
Fudan and Zhangjiang 2025 “Improve Quality, Increase Efficiency, and Reward” Action Plan
Fudan Zhangjiang Report on the Performance Evaluation of PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership)
Fudan Zhangjiang Voluntary Disclosure Notice Concerning Acceptance of Drug Marketing Applications for Obecholic Acid Tablets to Treat Primary Biliary Cholangitis
Fudan and Zhangjiang voluntarily disclosed an announcement on the completion of the US Phase II clinical trial of injectable hempofen to treat erythematous moles
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. voluntarily disclosed an announcement regarding the completion of the enrollment of the first subject in the phase III clinical trial of the injection of FDA018 antibody conjugate for the treatment of triple-negative breast cancer.
Announcement from Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Regarding the Resignation of Core Technical Personnel
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd voluntarily disclosed the announcement of completing the first subject enrollment in Phase I clinical trial for injection of FZ-AD005 antibody conjugate for the treatment of advanced solid tumors.
Rules of Procedures of the Board of Directors of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.
Announcement of resolutions from Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.'s 2023 Shareholders' Annual Meeting.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. voluntarily disclosed the completion of the first subject's enrollment in the Verification Clinical Trial of Oral Amantadine Hydrochloride Powder for Visualizing Glioma Surgery.